Business Description
Theriva Biologics Inc
NAICS : 325412
SIC : 2834
ISIN : US87164U1025
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 9.07 | |||||
Equity-to-Asset | 0.65 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | -0.09 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 36.8 | |||||
3-Year EPS without NRI Growth Rate | 44.3 | |||||
3-Year FCF Growth Rate | 42.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 19.64 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 19.72 | |||||
9-Day RSI | 23.35 | |||||
14-Day RSI | 26.88 | |||||
6-1 Month Momentum % | -70.42 | |||||
12-1 Month Momentum % | -74.87 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.88 | |||||
Quick Ratio | 2.88 | |||||
Cash Ratio | 2.42 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -80.3 | |||||
Shareholder Yield % | -0.44 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -57.66 | |||||
ROA % | -40.74 | |||||
ROIC % | -66.93 | |||||
3-Year ROIIC % | -34.26 | |||||
ROC (Joel Greenblatt) % | -962.13 | |||||
ROCE % | -42.92 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.06 | |||||
Price-to-Tangible-Book | 0.29 | |||||
EV-to-EBIT | 0.45 | |||||
EV-to-EBITDA | 0.46 | |||||
EV-to-FCF | 0.51 | |||||
Price-to-Net-Current-Asset-Value | 0.47 | |||||
Price-to-Net-Cash | 0.82 | |||||
Earnings Yield (Greenblatt) % | 222.22 | |||||
FCF Yield % | -471.77 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Theriva Biologics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -28.903 | ||
Beta | 0.76 | ||
Volatility % | 65.73 | ||
14-Day RSI | 26.88 | ||
14-Day ATR (€) | 0.033436 | ||
20-Day SMA (€) | 2.94 | ||
12-1 Month Momentum % | -74.87 | ||
52-Week Range (€) | 2.785 - 13.5 | ||
Shares Outstanding (Mil) | 1.35 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Theriva Biologics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Theriva Biologics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Theriva Biologics Inc Frequently Asked Questions
What is Theriva Biologics Inc(STU:SFY0)'s stock price today?
When is next earnings date of Theriva Biologics Inc(STU:SFY0)?
Does Theriva Biologics Inc(STU:SFY0) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |